CompletedN/Aketamine
Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies
Sponsored by Beth Israel Deaconess Medical Center
NCT ID
NCT05279898
Target Enrollment
70 participants
Start Date
2023-02-28
Est. Completion
2024-12-31
About This Study
In the PATHFINDER 2 trial, the study investigators will test the intraoperative EEG-guided multimodal general anesthesia (MMGA) management strategy in combination with a postoperative protocolized analgesic approach to: 1. reduce the incidence of perioperative neurocognitive dysfunction in cardiac surgical patients 2. ensure hemodynamic stability and decrease use of vasopressors in the operating rooms 3. reduce pain and opioid consumption postoperatively
Conditions Studied
Interventions
- •EEG Monitoring
- •Ropivacaine
- •Ketamine
- •Remifentanil
- •Dexmedetomidine
- •Rocuronium
- •Propofol
Eligibility
Age:60 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Age ≥ 60 years * Undergoing any of the following types of surgery with cardiopulmonary bypass limited to coronary artery bypass surgery (CABG), CABG+valve surgeries and isolated valve surgeries. Exclusion Criteria: * Preoperative left ventricular ejection fraction (LVEF) \<30% * Emergent surgery * Non-English speaking * Cognitive impairment as defined by total MoCA score \< 10 * Currently enrolled in another interventional study that could impact the primary outcome, as determined by the PI * Significant visual impairment * Chronic opioid use for chronic pain conditions with tolerance (total dose of an opioid at or more than 30 mg morphine equivalent for more than one month within the past year) * Hypersensitivity to any of the study medications * Known history of alcohol (\> 2 drinks per day) or drug abuse Active (in the past year) history of alcohol abuse (≥5 drinks/day for men or ≥4 drinks/day for women) as determined by reviewing medical record and history given by the patient * Liver dysfunction (liver enzymes \> 4 times the baseline, all patients will have a baseline liver function test evaluation), history and examination suggestive of jaundice.
Study Locations (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States